Antengene Corporation Limited (HKG:6996)
3.400
+0.030 (0.89%)
Jun 18, 2026, 11:55 AM HKT
Antengene Corporation Revenue
In the year 2025, Antengene Corporation had annual revenue of 105.34M CNY with 14.56% growth. Antengene Corporation had revenue of 52.16M in the half year ending December 31, 2025.
Revenue
105.34M CNY
Revenue Growth
+14.56%
P/S Ratio
19.53
Revenue / Employee
816.57K CNY
Employees
129
Market Cap
2.29B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 105.34M | 13.39M | 14.56% |
| Dec 31, 2024 | 91.95M | 24.65M | 36.62% |
| Dec 31, 2023 | 67.31M | -92.83M | -57.97% |
| Dec 31, 2022 | 160.14M | 131.37M | 456.62% |
| Dec 31, 2021 | 28.77M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Frontage Holdings | 2.00B |
| Viva Biotech Holdings | 1.92B |
| AIM Vaccine | 1.30B |
| Shandong Boan Biotechnology | 873.36M |
| BioDlink International Company | 831.99M |
| Jiangsu Recbio Technology | 14.16M |
| Clover Biopharmaceuticals | 3.90M |
| TYK Medicines | 117.25K |
Antengene Corporation News
- 3 months ago - Antengene Corporation Earnings release: H2 2025 - Filings
- 3 months ago - Antengene Corporation Slides: H2 2025 - Filings
- 3 months ago - Antengene Corporation Annual report: H2 2025 - Filings
- 3 months ago - Antengene Corporation Transcript: Status update - Transcripts
- 3 months ago - Antengene Corporation Press release: Status update - Filings
- 3 months ago - Antengene Corporation Slides: Status update - Filings
- 6 months ago - Antengene Secures Malaysian Approval For XPOVIO In Relapsed/Refractory DLBCL - Nasdaq
- 7 months ago - Antengene: NMPA Approves IND Application For Phase Ib/II CLINCH-2 Study With ATG-022 - Nasdaq